Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Hecla Mining Company Common Stock (HL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Hecla Mining Company Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Hecla Mining Company Common Stock trades at $15.06 (market cap $10.87B). The key difference: Hecla Mining Company Common Stock is far larger — about 3.8× Dyne Therapeutics Inc. Common Stock's market cap, and Hecla Mining Company Common Stock pays a 0.09% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Hecla Mining Company Common Stock for 3 Days on average.
| DYN | HL | |
|---|---|---|
Market Cap | $2.86B | $10.87B |
Volume | 3,341,579 | 31,516,848 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $31.81 |
52-Week Low | $14.60 | $11.97 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $2.18B | $10.40B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Hecla Mining (HL) trades at $16.18, down 3.92% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 51.68% gross margin and 19.15% net income margin, but recent quarterly earnings missed expectations. Positive news highlights a debt-free balance sheet and organic growth targeting over 20 million silver ounces, while institutional activity includes new investments from Bank of America and AlphaGrep.
The outlook is mixed: analyst consensus is a Buy with a $23.44 price target, implying 45% upside, but technical indicators signal near-term pressure. Key risks include silver price volatility and execution of growth projects. The stock presents a value opportunity for long-term investors if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Hecla Mining Company Common Stock
Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →
